It does not seem to be the case. Their has been 7-8M shares shorted for over a year now, and 7.9M short as of Jan. 15. They are not going away any time soon. What i can't figure out is why, of all the stocks and valuations out there - how they are making much on RMTI. Day trading OK, you might get lucky and ride a point. but at what price did they short in the last YEAR and make that much? the perfect short was out at 13 buy back at 9 (if you had perfect timing). Just does not seem that valuable of an effort.??
this will put at least 1M into the EBITA fold right off the bat this year, as that debt arrangement was awful, over 12% annually. Its done and off the books. Thats a good thing
like this stock for 2015. pending merger in Q1, huge insider buying. valuation is a screaming deal. stock is dead in the water, but that will change... big buy under 9. IMO
extremely positive elements and details on the call. headline is highly misleading for a 55 min. call and 200M in backlog heading into 2015. unreal.
there is only the commerical launch of 2 new fda approved drugs in 1H..... oh, and over 100M in cash to leverage a new deal... but thats all really.
solid days on high volume and holding over 50 and 100 day Moving averages. (plus the hard bounce off those averages last week, i think, at about 10.40. good overall techs, as well as story unfolding....
this qtr report in Feb. I anticipate news rolling out commercial production of Citr., with some timing details, and some followup of Triferic, with more general info on timing of rollout. We may get a surprise too, with a deal of liscensing or rumored purchase of a drug from another company? (now that they have cash to negiotiate)
la la long.
Do the work....
Rockwell Receives $20MM Upfront Cash; $15MM Equity Investment; $10MM in Milestone Payments Tied to Manufacturing Expansion
WIXOM, Mich., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has signed an exclusive agreement with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (NYSE:BAX), to commercialize Rockwell's hemodialysis concentrate product line in the U.S. and in select overseas markets.
Under the terms of the agreement, Baxter will become the exclusive distributor of Rockwell's hemodialysis concentrate and ancillary products in the U.S. and selected foreign countries for an initial term of 10 years. Baxter can extend the agreement for two additional 5-year terms upon meeting certain sales targets, coupled with a $7.5 million payment related to the first extension. Baxter will purchase products from Rockwell at a pre-determined gross margin-based price per unit and is required to meet minimum annual purchase levels in order to retain their exclusive rights. Baxter will leverage Rockwell's unique distribution operations in order to provide specialized customer and delivery service for concentrates, covering Rockwell's costs for these services. Rockwell will retain sales, marketing and distribution rights for its hemodialysis concentrate products in certain foreign countries in which it has an established commercial presence.
i predict a modest short cover, which will be good. but the negative types want desperately to be right, so we'll still have a big short position going forward, just slightly less. the stock clearly behaviors weird when good news comes out - so a ton of traders love to play games here.